Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zyvex Instruments was a pioneering nanotechnology company that specialized in the development of nanomanipulation and nano-probing systems. Founded as a division of Zyvex Corporation, the company provided essential tools for researchers to manipulate and characterize materials at the nanoscale within scanning electron microscopes (SEMs). Its flagship products, such as the S100 nanomanipulator, were utilized across semiconductor failure analysis, materials science, and life sciences for applications like cell manipulation and biomaterial testing. In 2007, the company was acquired by DCG Systems to bolster its portfolio of electrical characterization solutions. Following subsequent acquisitions, the technology is now integrated into the analytical instrumentation offerings of Thermo Fisher Scientific. The company is recognized for being the first to commercialize nanomanipulation systems for the global research market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zyvex Instruments.